banner.png
Confidence is your healing
Advantage
banner-overlay.png

From debridement to closure, LifeNet Health offers a portfolio of regenerative wound solutions to help give your patients the healing advantage.

Download the free E-Book

Navigating Wound Care Reimbursement with Confidence: A Guide to the New LCDs for CTPs

required

required

I consent to receiving relevant marketing messages from LifeNet Health.
dermacell-porous.png
DermACELL® Porous
The Porous Advantage

Human acellular dermal matrix

  • Intact dermal structure retains native ECM and growth factors. 1,2
  • Faster full incorporation.3
  • Proven to close wounds in four applications or less.4
Learn More
TheraSKIN®
The Viable Advantage

All-human skin allograft with living cells

  • Contains viable cells, endogenous growth factors, and a native extracellular matrix.2,5
  • Promotes 30% lower recidivism.6
  • Proven to close wounds in four applications or less.7
Learn More
thera-skin.png
matrion.png
Matrion®
The Powerful Advantage

Human placental allograft

  • 4x thicker than traditional bilayer grafts.8,9
  • Provides 50% more growth factors.9-11
  • Full-thickness durability promotes superior handling.
Learn More
Contact Us

Want to learn more about our comprehensive portfolio of regenerative wound solutions? Submit the form below and a member or our team will be in touch to learn about you and your team's needs.

required

required

I consent to receiving relevant marketing messages from LifeNet Health.
References
  1. 1. Agrawal H, Tholpady SS, Capito AE, Drake DB, Katz AJ. Macrophage phenotypes correspond with remodeling outcomes of various acellular dermal matrices. Open Journal of Regenerative Medicine. 2012; 01(03):51-59. https://doi.org/10.4236/ojrm.2012.13008
  2. 2. 68-20-047, Analysis of the Acellular Matrix, Growth Factors, and Cytokines Present in OrACELL.
  3. 3. LifeNet Health, TR ED-23-0306, In vivo Assessment of Local Tissue Response and Cell Infiltration - Animal study results may not be predictive of clinical results.
  4. 4. Cazzell, S., Vayser, D., Pham H., et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair and Regeneration. 2017.
  5. 5. LifeNet Health, TR 0292, LifeNet Health’s Decellularized Dermis, DermACELL, Comparison to the USP Monograph, Scaffold Human Dermis.
  6. 6. Barbul A, Gurtner GC, Gordon H, Bakewell K, Carter MJ. Matched-cohort study comparing bioactive human split-thickness skin allograft plus standard of care to standard of care alone in the treatment of diabetic ulcers: A retrospective analysis across 470 institutions. Wound Repair Regen. 2020 Jan;28(1):81-89. doi: 10.1111/wrr.12767. Epub 2019 Nov 1. Erratum in: Wound Repair Regen. 2020 May;28(3):431. PMID: 31587418; PMCID: PMC6972994.
  7. 7. Cazzell S, Vayser D, Pham H, Walters J, Reyzelman A, Samsell B, Dorsch K, Moore M. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair Regen. 2017 May;25(3):483-497. doi: 10.1111/wrr.12551. Epub 2017 Jun 12. PMID: 28544150.
  8. 8. Matrion Technical Monograph
  9. 9. LifeNet Health. TR-004-2020 Characterization of the Amnion, Chorion, and Trophoblast Layers of Decellularized and Freeze-Dried Placental Membrane. 2020.
  10. 10. LifeNet Health. IQOQ 19-306. Data on File. 2020.
  11. 11. LifeNet Health. ES-20-057 Data on File. 2020.